The present invention relates to crystalline forms of N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.本發明係關於N-[2-(3-羥基-3-甲基丁基)-6-(2-羥基丙烷-2-基)-2H-吲唑-5-基]-6-(三氟甲基)吡啶-2-甲醯胺之結晶型,其製備方法,包含其之醫藥組合物,及其控制病症之用途。